Dendrogenix is a biopharmaceutical company based in Liège (Belgium) dedicated to developing first in class molecules named "Dendrogenins" addressing important medical needs in the field of neurodegenerative diseases, in particular in Hearing Loss indication, and in the field of Cancer.